Anna S Tocheva
Overview
Explore the profile of Anna S Tocheva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Philips E, Liu J, Kvalvaag A, Morch A, Tocheva A, Ng C, et al.
Sci Immunol
. 2024 Mar;
9(93):eade6256.
PMID: 38457513
Programmed cell death-1 (PD-1) is a potent immune checkpoint receptor on T lymphocytes. Upon engagement by its ligands, PD-L1 or PD-L2, PD-1 inhibits T cell activation and can promote immune...
2.
Breen M, Fan X, Levy T, Pollak R, Collins B, Osman A, et al.
HGG Adv
. 2022 Oct;
4(1):100145.
PMID: 36276299
Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder caused at least in part by haploinsufficiency of the SHANK3 gene, due to sequence variants in SHANK3 or subtelomeric 22q13.3 deletions. Phenotypic...
3.
Lerrer S, Tocheva A, Bukhari S, Adam K, Mor A
iScience
. 2021 Sep;
24(9):103020.
PMID: 34522863
Despite the obvious inhibitory outcome of PD-1 signaling, an additional series of functions are activated. We have observed that T cells stimulated through the T cell receptor (TCR) and PD-1...
4.
Strazza M, Bukhari S, Tocheva A, Mor A
Immunology
. 2021 Jun;
164(3):555-568.
PMID: 34164813
Ligation of the inhibitory receptor PD-1 on T cells results in the inhibition of numerous cellular functions. Despite the overtly inhibitory outcome of PD-1 signalling, there are additionally a collection...
5.
Peled M, Tocheva A, Adam K, Mor A
Immunol Lett
. 2021 Mar;
233:42-47.
PMID: 33741379
Therapeutic programmed cell death protein 1 (PD-1) blockade enhances T cell mediated anti-tumor immunity but many patients do not respond and a significant proportion develops inflammatory toxicities. To develop better...
6.
Adam K, Iuga A, Tocheva A, Mor A
PLoS One
. 2021 Feb;
16(2):e0246168.
PMID: 33571254
Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a variety of cancers, however their therapeutic potential is limited by abstruse immune related adverse events. Currently, no robust...
7.
Tocheva A, Peled M, Strazza M, Adam K, Lerrer S, Nayak S, et al.
J Biol Chem
. 2020 Oct;
295(52):18036-18050.
PMID: 33077516
Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor that limits excessive T cell responses. Cancer cells have evolved to evade these immunoregulatory mechanisms by upregulating PD-1 ligands...
8.
Tocheva A, Lerrer S, Mor A
Curr Protoc Immunol
. 2020 Aug;
130(1):e103.
PMID: 32757378
Our understanding of programmed cell death 1 (PD-1) biology is limited due to technical difficulties in establishing reproducible, yet simple, in vitro assays to study PD-1 signaling in primary human...
9.
Breen M, Bierer L, Daskalakis N, Bader H, Makotkine I, Chattopadhyay M, et al.
Transl Psychiatry
. 2020 Feb;
10(1):1.
PMID: 32066695
This Article was originally published without the correct Supplemental Table file (Table S1 was missing). In total, there are seven Supplemental Tables, and six were in the original submission. Furthermore,...
10.
Philips E, Garcia-Espana A, Tocheva A, Ahearn I, Adam K, Pan R, et al.
J Biol Chem
. 2019 Dec;
295(14):4372-4380.
PMID: 31882544
Programmed cell death protein 1 (PD-1) is an inhibitory receptor on T lymphocytes that is critical for modulating adaptive immunity. As such, it has been successfully exploited for cancer immunotherapy....